ETR:BIO Biotest Aktiengesellschaft (BIO) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free BIO Stock Alerts €42.80 +0.20 (+0.47%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range€42.80▼€42.8050-Day Range€42.00▼€42.8052-Week Range€39.60▼€44.00Volume10 shsAverage Volume1,927 shsMarket Capitalization$847.01 millionP/E Ratio18.69Dividend Yield0.09%Price TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Biotest Aktiengesellschaft alerts: Email Address Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About Biotest Aktiengesellschaft Stock (ETR:BIO)Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.Read More BIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIO Stock News HeadlinesMarch 10, 2024 | finance.yahoo.comBiotest Aktiengesellschaft (BIOD.XC)March 9, 2024 | benzinga.comBiotest AG's Net WorthMarch 28, 2024 | DTI (Ad)CBOE shift unlocks new weekend income strategyYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. December 13, 2023 | wsj.comBiotest AG Pfd.October 5, 2023 | markets.businessinsider.comEQS-Adhoc: Biotest AG: Peter Janssen appointed new Chairman of the Board of Biotest AGOctober 5, 2023 | finanznachrichten.deEQS-Adhoc: Biotest AG: Erhöhung der EBIT PrognoseOctober 5, 2023 | markets.businessinsider.comEQS-Adhoc: Biotest AG: Increase of the EBIT guidanceMay 19, 2023 | morningstar.comBiotest AG Pfd Shs - Non-votingMarch 28, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.May 18, 2023 | investing.comHangzhou Biotest Biotech Co Ltd (688767)April 28, 2023 | markets.businessinsider.comEQS-Adhoc: Biotest AG: Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raisedApril 22, 2023 | wsj.comHangzhou Biotest Biotech Co. Ltd. AMarch 19, 2023 | finanznachrichten.deBiotech Report: Biotest und BB Biotech behauptet, MorphoSys tiefrotMarch 16, 2023 | de.finance.yahoo.comBiotest AG: Biotest spendet Humanalbumin für Erdbebenopfer in der TürkeiMarch 16, 2023 | uk.finance.yahoo.comBiotest AG: Biotest donates human albumin for earthquake victims in TurkeyFebruary 16, 2023 | marketwatch.com2023 Platelet-rich Fibrin Market Growth in 2029 Dominant Forces in Industry with Top Regions and PlayersJuly 27, 2022 | finance.yahoo.comBiotest Aktiengesellschaft (BIO3.DE)March 30, 2022 | finanznachrichten.deALCON AGFebruary 16, 2022 | markets.businessinsider.comDGAP-Adhoc: Biotest AG: Biotest exceeds Revenue guidance 2021January 7, 2022 | markets.businessinsider.comDGAP-Adhoc: Biotest AG: Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offerDecember 9, 2021 | uk.finance.yahoo.comBiotest AG: Reduction of guidanceDecember 8, 2021 | markets.businessinsider.comDGAP-Adhoc: Biotest AG: Reduction of guidanceSeptember 19, 2021 | seekingalpha.comGrifols, S.A. (GRFS)See More Headlines Receive BIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotest Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolETR:BIO CUSIPN/A CIKN/A Webwww.biotest.com Phone+49-6103-8010FaxN/AEmployees2,228Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)€2.29 Trailing P/E Ratio18.69 Forward P/E Ratio356.67 P/E GrowthN/ANet Income$90.90 million Net Margins13.87% Pretax MarginN/A Return on Equity22.62% Return on Assets6.39% Debt Debt-to-Equity Ratio151.29 Current Ratio5.00 Quick Ratio1.66 Sales & Book Value Annual Sales$655.60 million Price / Sales1.29 Cash Flow€1.38 per share Price / Cash Flow31.04 Book Value€9.38 per share Price / Book4.56Miscellaneous Outstanding Shares19,790,000Free FloatN/AMarket Cap$847.01 million OptionableNot Optionable Beta0.27 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Peter Janssen (Age 56)Chairman of the Board of Management Comp: $288kDr. Jorg Schuttrumpf (Age 50)Chief Scientific Officer & Member of the Management Board Comp: $581kDirk Schuck (Age 46)Member of Supervisory Board Ms. Ainhoa Mendizabal Zubiaga (Age 51)Member of Management Board & CFO Dr. Monika ButtkereitHead of Investor RelationsDr. Christina ErbHead of Corporate HRMore ExecutivesKey CompetitorsMorphoSysETR:MORRHÖN-KLINIKUM AktiengesellschaftETR:RHKStratecETR:SBSDrägerwerk AG & Co. KGaAETR:DRW3CompuGroup Medical SE & Co. KGaAETR:COPView All Competitors BIO Stock Analysis - Frequently Asked Questions How have BIO shares performed in 2024? Biotest Aktiengesellschaft's stock was trading at €42.60 on January 1st, 2024. Since then, BIO stock has increased by 0.5% and is now trading at €42.80. View the best growth stocks for 2024 here. Is Biotest Aktiengesellschaft a good dividend stock? Biotest Aktiengesellschaft (ETR:BIO) pays an annual dividend of €0.04 per share and currently has a dividend yield of 0.18%. The dividend payout ratio is 1.75%. This payout ratio is at a healthy, sustainable level, below 75%. What other stocks do shareholders of Biotest Aktiengesellschaft own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biotest Aktiengesellschaft investors own include Grifols (GRFS), CSL (CSL), BioXcel Therapeutics (BTAI) and ADMA Biologics (ADMA). This page (ETR:BIO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotest Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.